SAN DIEGO, May 12, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will present at the UBS 2015
Global Health Care Conference in New
York, on Monday, May
18th, 2015 at 2:00 p.m.
ET/11:00 a.m. PT. Dr.
Helen Torley, president and chief
executive officer, will provide a corporate overview.
The presentation will be webcast through the "Investors" section
of Halozyme's corporate website at halozyme.com, and a recording
will be made available for 90 days following the event. To access
the live webcast, please log on to Halozyme's website approximately
15 minutes prior to the presentation to register and download any
necessary audio software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, our investigational drug
PEGPH20, applies a unique approach to targeting solid tumors,
allowing increased access of co-administered cancer drug therapies
to the tumor. PEGPH20 is currently in development for
metastatic pancreatic cancer and non-small cell lung cancer and has
potential across additional cancers in combination with different
types of cancer therapies. In addition to its proprietary product
portfolio, Halozyme has established value-driving partnerships with
leading pharmaceutical companies including Roche, Pfizer, Janssen
and Baxter for its drug delivery
platform, ENHANZE™, which enables biologics and small molecule
compounds that are currently administered intravenously to be
delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit
halozyme.com.
Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-ubs-2015-global-health-care-conference-300082110.html
SOURCE Halozyme Therapeutics, Inc.